SecurityCACQ / Caesars Acquisition Co. (12768T103)
President and CEOGarber Mitchell Alan
IndustryHotels and Motels
Institutional Owners6
Institutional Shares2,143,824 - 1.54%
Common Shares Outstanding138,984,958 shares (as of 2017-06-30)
Institutional Value$ 28,988,000 USD

Institutional Stock Ownership and Shareholders

Caesars Acquisition Co. (NASDAQ:CACQ) has 6 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,143,824 shares. Largest shareholders include BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, BlackRock Group LTD, BlackRock Advisors LLC, and Americafirst Quantitative Trust - Americafirst Defensive Growth & Income Portfolio, Series 2.
Caesars Acquisition Co. (NASDAQ:CACQ) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-08-15 13F-HR Americafirst Quantitative Trust - Americafirst Defensive Growth & Income Portfolio, Series 2 8,392 160
2017-02-10 13F-HR BlackRock Investment Management, LLC 193,491 192,586 -0.47 2,403 2,600 8.20
2017-02-10 13F-HR BlackRock Group LTD 18,154 20,593 13.44 225 278 23.56
2017-11-16 13F-HR AMERICAFIRST CAPITAL MANAGEMENT, LLC 8,392 0 -100.00 160 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 1,210,927 1,435,258 18.53 15,040 19,376 28.83
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 450,733 468,748 4.00 5,598 6,328 13.04
2017-02-10 13F-HR BlackRock Advisors LLC 17,347 18,247 5.19 215 246 14.42

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Caesars: A Misunderstood Bankruptcy Reorg With 100%+ Upside

2018-09-12 seekingalpha
Investors appear to be underappreciative of Caesars’ growth playbook through sale-leaseback arbitrage transactions with VICI (REIT), while at the same time acquiring incremental properties and implementing property level improvements through Total Rewards. (6-0)

Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update

2018-09-02 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018. (52-3)

Tracking George Soros's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha
Soros' 13F portfolio value increased from $6.16B to $6.25B this quarter. The number of positions decreased from 219 to 203. (138-9)

Caesars Entertainment Corp. (CZR) CEO Mark Frissora on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Hello, and welcome to today's webcast. My name is Sarah, and I will be your event specialist. All lines have been placed on mute to prevent any background noise. Please note that today's webcast is being recorded. [Operator Instructions] (4-0)

Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017. (1229-11)

CUSIP: 12768T103